Phase 2Completed
Salvage Ovarian FANG™ Vaccine + Bevacizumab
Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) Integrated With Bevacizumab for Patients With Recurrent/Refractory Ovarian Cancer Participating in Study CL-PTL 105
- Sponsor
- Gradalis, Inc. (Industry)
- Enrollment
- 5 enrolled
- Conditions
- Stage III Ovarian Cancer; Stage IV Ovarian Cancer
- Interventions
- Vigil™ Vaccine; Bevacizumab
- Ages
- adults, older adults
- Registry
- NCT01551745
Full record on ClinicalTrials.gov
From the registry
This is a Phase II study of Vigil™ autologous tumor cell vaccine integrated with bevacizumab. All patients will have had Vigil™ prepared and stored from initial primary surgical debulking. Patients meeting eligibility criteria will receive Vigil™ 1.0 x 10e7 cells/intradermal injection once every 4 weeks and bevacizumab 10 mg/kg intravenously every 2 weeks.
Primary outcomes
- Time to Progression
- Response Rate
History
Last registry update
Results first posted
Primary completion
Started
Registered